A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

April 12, 2026

Study Completion Date

January 26, 2027

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Encorafenib

capsule

BIOLOGICAL

Cetuximab

IV

BIOLOGICAL

Pembrolizumab

IV

Trial Locations (64)

1070

Institut Jules Bordet, Anderlecht

1200

Cliniques universitaires Saint-Luc, Brussels

2100

Rigshospitalet, Copenhagen

2730

Herlev and Gentofte Hospital, Copenhagen

2820

Imelda General Hospital, Bonheiden

3000

Peter MacCallum Cancer Centre, Melbourne

3052

Royal Melbourne Hospital, Parkville

3084

Austin Health, Heidelberg

7100

Vejle Sygehus, Vejle

9000

Aalborg Universitetshospital, Syd, Aalborg

10060

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo

14059

Fakultni Thomayerova nemocnice, Prague

15706

CHUS - Hospital Clinico Universitario, Santiago de Compostela

20141

Istituto Europeo di Oncologia IRCCS, Milan

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

20249

Facharztzentrum Eppendorf, Hamburg

25124

Fondazione Poliambulanza Istituto Ospedaliero, Brescia

28007

Hospital General Universitario Gregorio Marañon, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

33140

Mount Sinai Cancer Center, Miami Beach

34298

Institut Regional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier

35128

Istituto Oncologico Veneto IRCCS, Padua

38138

The West Clinic, PLLC dba West Cancer Center, Germantown

41013

Hospital Universitario Virgen Del Rocio, Seville

42016

Ospedale di Guastalla, Guastalla

42123

Arcispedale Santa Maria Nuova, Reggio Emilia

46014

Hospital General Universitario de Valencia, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

56126

Azienda Ospedaliero Universitaria Pisana, Pisa

57124

Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno, Livorno

63100

Centre Hospitalier Universitaire Estaing, Clermont-Ferrand

CHU Estaing, Clermont-Ferrand

71013

IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo

75015

Hôpital Européen Georges Pompidou, Paris

75571

Hôpital Saint Antoine, Paris

77030

MD Anderson Cancer Center, Houston

80131

"Azienda Ospedaliera Universitaria dell'Università Luigi Vanvitelli Piazza Luigi Miraglia, 2 Napoli", Napoli

81737

Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie, Munich

85054

Mayo Clinic Building - Phoenix, Phoenix

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic, Scottsdale

90033

Keck Hospital of USC, Los Angeles

Keck School of Medicine of USC, Los Angeles

LAC USC Medical Center, Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles

USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles

USC/Norris Comprehensive Cancer Center, Los Angeles

91105

Keck Hospital of USC Pasadena, Pasadena

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M4N 3M5

Sunnybrook Health Sciences - Odette Cancer Centre, Toronto

S7N4H4

Saskatoon Cancer Center, Saskatoon

500 05

Fakultni nemocnice Hradec Kralove, Hradec Králové

180 81

Fakultni nemocnice Bulovka, Prague

09042

Policlinico Universitario Monserrato, Monserrato

6229 HX

Maastricht UMC+, Maastricht

0450

Oslo Universitetssykehus Ullevål, Oslo

62-500

Przychodnia Lekarska KOMED, Konin

36-200

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozów

833 10

Narodny onkologicky ustav, Bratislava

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08908

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

B9 5SS

Heartlands Hospital, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05217446 - A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter